A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks

In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.

FDA gave Novo Nordisk AS an early Christmas gift with the Dec. 23 approval of Saxenda (liraglutide) for chronic weight management, with no requirement for a new cardiovascular outcomes trial of the GLP-1 receptor agonist. The approval came two months after the original Oct. 20 user fee date passed without action.

Saxenda is indicated for chronic weight management, in addition to a reduced-calorie diet and physical activity, in adults with a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America